SLMAP and EPO Genetic Polymorphism in Diabetic Retinopathy
NCT ID: NCT05344690
Last Updated: 2024-02-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
180 participants
OBSERVATIONAL
2022-05-20
2023-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Observational Study to Assess Genotypes/Phenotypes Correlations in Type-2 Diabetic Retinopathy
NCT01228981
Relationship Between Dyslipidemia and The Response of Diabetic Macular Edema to Intravitreal Injection of Anti Vascular Endothelial Growth Factor Agents
NCT06205979
Glycemic Control and Diabetic Macular Edema
NCT01358396
Assessment Of Diabetic Maculopathy Changes After Phacoemulsification by Using Optical Coherence Tomography
NCT05547789
Studying a Potential Protective Effect of L-Dopa on Retinitis Pigmentosa
NCT02837640
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Several studies suggest variations in diabetic retinopathy prevalence depending on racial background and genetic polymorphism.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
cases
diabetic patients suffering from clinically confirmed diabetic retinopathy
SLMAP and EPO genetic polymorphism
Presence of EPO gene SNP rs551238 and SLMAP rs17058639 gene polymorphisms
controls
matched (based on gender and duration of diabetes) diabetic patients free from diabetic retinopathy will be recruited.
SLMAP and EPO genetic polymorphism
Presence of EPO gene SNP rs551238 and SLMAP rs17058639 gene polymorphisms
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SLMAP and EPO genetic polymorphism
Presence of EPO gene SNP rs551238 and SLMAP rs17058639 gene polymorphisms
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Type 2 DM
* Duration of diabetes from 5-10 years
* Egyptian patients
Exclusion Criteria
30 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rana Sayed Fouad
Principal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lamiaa M El Wakeel, PhD
Role: STUDY_CHAIR
Faculty of Pharmacy, Ain Shams University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ain Shams University Hospitals
Cairo, Abbasseya, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RHDIRB2020110301 REC 72
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.